Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 14;47(4):895–906. doi: 10.1007/s00259-019-04601-3

Fig. 4: NETest level alterations based upon the PPQ status (n=122).

Fig. 4:

4A. Dynamics of the biomarker and treatment. PPQ-positive (n=81) (blue) were associated with a significant decrease (*p<0.05) in the NETest following PRRT. Levels at follow-up fell into the SD category. In those in whom PRRT was predicted to “fail” (PPQ-negative) (red), the mean NETest was initially unchanged and thereafter significantly increased (*p<0.05). Levels at RECIST-defined progression fell into the PD category.

4B. Mean changes in the NETest in PPQ-positive (n=81; decreased from pre-PRRT) compared to PPQ-negative subjects (n=41; net increase from baseline). Levels were significantly different (p<0.0001).

4C. Individual alterations in absolute NETest levels from pre-PRRT (open circles) to end of therapy/progression with red arrows indicative of an increase (and category change) and blue arrows a decrease (and category change).